PAPERS DISCUSSED BY DR LEONARD (HEMATOLOGIC MALIGNANCIES)

Pfreundschuh M et al. Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab: Results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Proc ASCO 2008;Abstract 8508.

Czuczman MS et al. International study of lenalidomide in relapsed/refractory aggressive non-Hodgkin’s lymphoma. Proc ASCO 2008;Abstract 8509.

Palumbo AP et al. Bortezomib, pegylatedlyposomal-doxorubicin and dexamethasone (PAD) as induction therapy prior to reduced intensity autologous stem cell transplant (ASCT) followed by lenalidomide and prednisone (LP) as consolidation and lenalidomide alone as maintenance. Proc ASCO 2008;Abstract 8518.

List AF et al. Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission. Proc ASCO 2008;Abstract 7006.

Mauro MJ et al. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). Proc ASCO 2008;Abstract 7009.

Kantarjian H et al. Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results. Proc ASCO 2008;Abstract 7010.